AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions of claims in the application.

- 1-14 (Canceled).
- 15. (Currently Amended) A method for maintaining or improving the visual acuity and the field of vision in a patient in need of such treatment, said method comprising:

administering a drug comprising an inhibitor of the enzyme that converts angiotensin I to angiotensin II ramipril, wherein said drug maintains or improves visual acuity and the field of vision.

- 16. (Currently Amended) The method according to claim 15, wherein said inhibitor of the enzyme that converts angiotensin I to angiotensin II drug is an ophthalmic neuro-protector and/or a retinoprotector.
- 17. (Canceled) The method according to claim 15, wherein said inhibitor has: an equilibrium inhibition constant K_i that governs the *in vitro* inhibition of rabbit converting enzyme by the inhibitor, wherein the constant is lower than that of enalaprilat (50 pmol/l); and

a constant k_4 for the reversible isomerization of the enzyme-inhibitor complex formed, wherein said constant k_4 is lower than that of the complex formed by enalaprilat and the converting enzyme (1.1 x 10^{-4}) in a medium of 50 mM/l Hepes, 300 mmol/l NaCl, 1 micromol/L ZnCl₂, pH 7.5.

- 18. (Canceled) The method according to claim 15, wherein vasodilatory activity of the inhibitor is present in the arteries and veins.
 - 19. (Canceled) The method according to claim 15, wherein said drug comprising

said inhibitor is more lipophilic than enalaprilat.

- 20. (Canceled) The method according to claim 15, wherein said drug comprising said inhibitor is selected from the group of: ramipril, ramiprilat, a pharmaceutically acceptable salt of ramipril, a pharmaceutically acceptable salt of ramiprilat and derivatives thereof, wherein said derivatives can liberate ramiprilat into said patient.
- 21. (Currently Amended) The method according to claim 15, wherein said drug comprising said inhibitor is administered orally.
- 22. (Currently Amended) The method according to claim 21, wherein said inhibitor in said drug ramipril is administered at a dose of 0.5 to 5 mg/day.
- 23. (Currently Amended) The method according to claim 21, wherein said inhibitor in said drug ramipril is administered at a dose of 1 to 2 mg/day.
- 24. (Currently Amended) The method according to claim 21, wherein said inhibitor in said drug ramipril is administered at a dose of 1.25 mg/day.
- 25. (Currently Amended) The method according to claim 15, wherein said drug comprising said inhibitor is administered parenterally.
- 26. (Currently Amended) The method according to claim 25, wherein said drug comprising said inhibitor is administered intravenously or intramuscularly or transdermically or topically.
 - 27. (Currently Amended) The method according to claim 26, wherein said drug

comprising said inhibitor is administered topically to the eye.

- 28. (Previously Presented) The method according to claim 27, wherein said drug is administered as an ophthalmic solution.
- 29. (Previously Presented) The method according to claim 15, wherein said patient has a degenerating chorioretinopathy or has an optic neuropathy or has both a degenerating chorioretinopathy and an optic neuropathy.
- 30. (Previously Presented) The method according to claim 15, wherein said patient has a glaucomatous neuropathy.
- 31. (Previously Presented) The method according to claim 15, wherein said patient has a degenerative chorioretinopathy in severe myopia.
- 32. (Previously Presented) The method according to claim 15, wherein said patient has age-related macular degeneration with or without sub-retinal neovessels.
- 33. (Previously Presented) The method according to claim 15, wherein said patient has a central serous chorioretinopathy or a chronic central serous chorioretinopathy.
- 34. (Previously Presented) The method according to claim 15, wherein said patient has a hereditary dystrophy of the retina.
- 35. (Previously Presented) The method according to claim 34, wherein said hereditary dystrophy of the retina is a retinitis pigmentosa.

- 36. (Previously Presented) The method according to claim 15, wherein said patient has a retinal venous occlusion.
- 37. (Previously Presented) The method according to claim 15, wherein said patient is aged.
- 38. (Canceled) A method for maintaining or improving the visual acuity and the field of vision in a patient in need of such treatment, said method comprising:

administering an ophthalmic drug comprising as an active ingredient ramipril or ramiprilat.